Filing Details

Accession Number:
0000904454-12-000032
Form Type:
5
Zero Holdings:
No
Publication Time:
2012-01-24 18:21:06
Reporting Period:
2011-12-31
Filing Date:
2012-01-24
Accepted Time:
2012-01-24 18:21:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1279695 Universal Biosensors Inc UBI Surgical & Medical Instruments & Apparatus (3841) 980424072
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
200406 Johnson & Johnson One Johnson &Amp; Johnson Plaza
New Brunswick NJ 08933
No No Yes No
924020 Johnson & Johnson Development Corp Et Al One Johnson &Amp; Johnson Plaza
New Brunswick NJ 08933
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-03-08 25,000 $1.41 17,406,617 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-03-09 25,000 $1.42 17,381,617 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-03-10 25,000 $1.40 17,356,617 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-03-21 4,900 $1.36 17,351,717 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-03-29 32 $1.38 17,351,685 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-03-30 155 $1.39 17,351,530 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-04-14 10,000 $1.41 17,341,530 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-04-15 7,500 $1.42 17,334,030 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-04-18 8,000 $1.42 17,326,030 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-04-20 10,000 $1.44 17,316,030 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-04-21 35,000 $1.49 17,281,030 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-04-27 10,000 $1.51 17,271,030 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-04-28 10,000 $1.52 17,261,030 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-04-29 10,000 $1.53 17,251,030 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-07-28 341 $1.30 17,250,689 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-08-01 752 $1.19 17,249,937 No 4 S Indirect By Johnson & Johnson Development Corporation
Common Stock Disposition 2011-09-08 1,500,000 $0.96 15,749,937 No 4 S Indirect By Johnson & Johnson Development Corporation
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
No 4 S Indirect By Johnson & Johnson Development Corporation
Footnotes
  1. The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person.